சோடியம் சேனல் தடுப்பான்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சோடியம் சேனல் தடுப்பான்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சோடியம் சேனல் தடுப்பான்கள் Today - Breaking & Trending Today

Cadila Healthcare rises after USFDA nod for anti-depressant drug

Cadila Healthcare gained 1.97% to Rs 442.45 after the drug maker said it received a final approval from the US drug regulator to market nortriptyline hydrochloride capsules 10 mg, 25 mg, 50 mg and 75 mg.The medication is used to treat mental/mood problems such as depression. The drug will be manufactured at the group s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Separately, Cadila Healthcare announced that its US subsidiary has acquired experimental drug from Cyprium for treating Menkes disease. Cyprium Therapeutics, a partner of Fortress Biotech, and Sentynl Therapeutics, a US- based specialty pharmaceutical company owned by the Zydus Group, has announced its execution of an asset purchase agreement to commit development funding for and acquire Cyprium s proprietary rights to CUTX-101, its Copper Histidinate product candidate for th ....

Zydus Group , Cadila Healthcare , Fortress Biotech , Sentynl Therapeutics , Copper Histidinate , Capital Market , Branches Of Biology , Receptor Antagonists , Muscarinic Antagonists , Serotonin Antagonists , Sodium Channel Blockers , Tricyclic Antidepressants , Mg Cars , Health Care , ஜய்துச் குழு , காடிலா சுகாதாரம் , கோட்டை பயோடெக் , மூலதனம் சந்தை , கிளைகள் ஆஃப் உயிரியல் , சோடியம் சேனல் தடுப்பான்கள் , மிகி கார்கள் , ஆரோக்கியம் பராமரிப்பு ,

Zydus Cadila receives USFDA approval for Nortriptyline Hydrochloride Capsules

This medication is used to treat mental/mood problems such as depression.
It may help improve mood
and feelings of well-being, relieve anxiety and tension, and increase one s energy level. The drug will
be manufactured at the group s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of
the filing process in FY 2003-04.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these dif ....

Zydus Cadila , Nortriptyline Hydrochloride Capsules , Pamelor Capsules , Capital Market , Branches Of Biology , Receptor Antagonists , Companies Based In Ahmedabad , Muscarinic Antagonists , Serotonin Antagonists , Sodium Channel Blockers , Tricyclic Antidepressants , Cadila Healthcare , Mg Cars , Magnesium In Biology , ஜய்துச் காடிலா , மூலதனம் சந்தை , கிளைகள் ஆஃப் உயிரியல் , நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத் , சோடியம் சேனல் தடுப்பான்கள் , காடிலா சுகாதாரம் , மிகி கார்கள் , வெளிமம் இல் உயிரியல் ,